ExThera Medical’s CEO Bob Ward Receives Prestigious BioMedSA Award for Innovation in Healthcare and Bioscience Including a Groundbreaking Device to Treat COVID-19

Editor’s note:  Robert Ward, member of the Scientific Advisory Committee of Xi′an Eyedeal Medical Technology Co., Ltd. and academician of the American Academy of Engineering, invented Seraph 100, which won the 2021-2022 Biomed SA Award for Innovation in Health Care and Bioscience.

MARTINEZ, Calif. – On September 8th, BioMedSA honored Robert Ward, President and CEO of ExThera Medical, with the 2021-2022BioMedSA Award for Innovation in Healthcare and Bioscience, for his numerous achievements in the medical device industry, including the development of the Seraph® 100 Microbind®Affinity Blood Filter, a groundbreaking device that has been used in the treatment of critically ill COVID-19 patients. The ceremony was held in the new Tech Center in Port San Antonio TX.  It was attended by more than 400 people, including clinicians and administrators and the mayor of San Antonio TX, a major hub of MedTech and military and civilian medicine.

The BioMedSA Award for Innovation in Healthcare and Bioscience celebrates local and national innovators in the healthcare and bioscience field, including patient care, education, research and development, leadership, public policy, and medical technology.  The list of past winners is a who’s who of the field.

The picture comes from the network.

“We are happy that the Seraph 100 is making a positive impact during the COVID-19 pandemic under our FDA Emergency Use Authorization,” said ExThera Medical CEO Robert Ward. “It is an incredible honor to be recognized by one’s peers and by a highly regarded organization such as BioMedSA.”
Prior to ExThera Medical, Robert Ward led several companies whose innovations have benefitted patients, including as President/CEO and founder of the Polymer Technology Group (PTG), President of the Biomaterials Division at Thoratec and Director of Research at Avco Medical Products. He has numerous technical publications and patents and has received multiple awards and recognitions.
“We are proud to honor Robert Ward for his lifetime of achievements in the MedTech industry,” noted BioMedSA President Heather Hanson. “His entire career of innovation, invention and commercialization of technologies has made an indelible impact on patients around the world, most recently during the COVID-19 pandemic.”

The Seraph 100 has been granted Emergency Use Authorization by the Food and Drug Administration to treat COVID-19 patients admitted to the ICU with confirmed or imminent respiratory failure, and has been used on more than 1,000 US and EU patients since April 2020. A multicenter randomized controlled trial studying blood purification for the treatment of pathogen-associated shock during sepsis (PURIFY-RCT) began enrollment earlier this year.  Seraph attained a CE Mark in the EU countries where it has been used successfully to treat COVID-19 and a variety of other bloodstream infections.